Details of Disease

General Information of Disease (ID: DISTS43D)

• Disease Name: Post-transplant lymphoproliferative disorder
• Synonyms: PTLD; post-transplant lymphoproliferative disorder
• Disease Class: 2B32: Immunoproliferative disorder
• Definition: Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)
• Disease Hierarchy:
  DISC43DK: Disease related to transplantation
  DISTS43D: Post-transplant lymphoproliferative disorder
• ICD Code:
  ICD-11: ICD-11: 2B32
  ICD-10: ICD-10: D47.Z1
  ICD-9: ICD-9: 238.77
  Expand ICD-11: 'XH2R75
  Expand ICD-9: 238.77
• Disease Identifiers:
  MONDO ID: MONDO_0019088
  UMLS CUI: C0432487
  MedGen ID: 98160
  Orphanet ID: 70568
  SNOMED CT ID: 1155771008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Tabelecleucel	DM5Z8ID	Phase 3	Cell therapy	[1]
Baltaleucel-T	DM3WCL4	Phase 2	NA	[2]
EBV-CTL	DMU3HYY	Phase 2	NA	[3]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT03394365) Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)